Pandion Therapeutics, Inc.
https://pandiontx.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Pandion Therapeutics, Inc.
Merck & Co. CEO Davis Debuts With A Leaner Organization And Money To Spend
Merck's new CEO Robert Davis talked about his vision for business development and how the company might use the $9bn gained from the spinout of Organon.
Merck & Co.'s Transitional Year Is Off To A Sluggish Start
The company, in the midst of a leadership and structural transition, said the pandemic negatively impacted revenues by about $600m.
Merck & Co. Buys Pandion, Building Out Capability In Autoimmune Disease
Merck & Co. reached a deal to acquire the developer of targeted immune modulators for $1.85bn. Pandion CEO Kakkar talked to Scrip about the acquisition.
OliX Diversifies Into mRNA Amid Growing Global Interest
Amid the highly successful launch of COVID-19 vaccines using the technology by Pfizer/BioNTech and Moderna, South Korean bioventure OliX Pharmaceuticals is diversifying into the mRNA field by establishing a new subsidiary that focuses on R&D into new vaccines and therapeutics using the platform.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
- Other Names / Subsidiaries
-
- Merck & Co., Inc.